CY1109858T1 - Αλογονομενοι επιλεκτικοι ρυθμιστες υποδοχεα ανδρογονων & μεθοδοι χρησης τους - Google Patents

Αλογονομενοι επιλεκτικοι ρυθμιστες υποδοχεα ανδρογονων & μεθοδοι χρησης τους

Info

Publication number
CY1109858T1
CY1109858T1 CY20091100794T CY091100794T CY1109858T1 CY 1109858 T1 CY1109858 T1 CY 1109858T1 CY 20091100794 T CY20091100794 T CY 20091100794T CY 091100794 T CY091100794 T CY 091100794T CY 1109858 T1 CY1109858 T1 CY 1109858T1
Authority
CY
Cyprus
Prior art keywords
androgen receptor
subject
halogenated
methods
chf
Prior art date
Application number
CY20091100794T
Other languages
English (en)
Inventor
James T Dalton
Duane D Miller
Donghua Yin
Yali He
Mitchell S Steiner
Karen A Veverka
Original Assignee
University Of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/270,732 external-priority patent/US6998500B2/en
Application filed by University Of Tennessee Research Foundation filed Critical University Of Tennessee Research Foundation
Publication of CY1109858T1 publication Critical patent/CY1109858T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04Derivatives of thiourea
    • C07C335/16Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/18Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση παρέχει μία κατηγορία παραγόντων στόχευσης υποδοχέα ανδρογόνου (ARTA). Οι παράγοντες καθορίζουν μία νέα υποκατηγορία ενώσεων, οι οποίες είναι επιλεκτικοί ρυθμιστές υποδοχέα ανδρογόνου (SARM). Αρκετές από τις ενώσεις SARM έχουν βρεθεί να έχουν μία απρόσμενη αντιανδρογονική και αναβολική δραστηριότητα ενός μη στεροειδούς συνδέσμου για τον υποδοχέα ανδρογόνου. Οι ενώσεις SARM είτε αυτόνομα είτε ως μία σύνθεση είναι χρήσιμες για α) για την αντισύλληψη του άνδρα· β) για τη θεραπεία μίας ποικιλίας ασθενειών οι οποίες σχετίζονται με τις ορμόνες, για παράδειγμα οι ασθένειες που συνδέονται με την μείωση ανδρογόνων σε ηλικιωμένους άνδρες (Androgen Decline in Aging Male) (ADAM), όπως η κόπωση, η κατάθλιψη, η μειωμένη λίμπιντο, η σεξουαλική δυσλειτουργία, η στυτική δυσλειτουργία, ο υπογοναδισμός, η οστεοπόρωση, η τριχόπτωση, η αναιμία, η παχυσαρκία, η σαρκοπενία, η οστεοπενία, η οστεοπόρωση, η καλοήθης υπερπλασία του προστάτη, οι διαταραχές στη διάθεση και στη νοητική λειτουργία και καρκίνο του προστάτη· γ) θεραπεία των ασθενειών που συνδέονται με την μείωση ανδρογόνων στις γυναίκες Androgen Decline in Female (ADIF), όπως η σεξουαλική δυσλειτουργία, η μειωμένη σεξουαλική λίμπιντο, ο υπογοναδισμός, η σαρκοπενία, η οστεοπενία, η οστεοπόρωση, οι διαταραχές στη νοητική λειτουργία και στη διάθεση, η κατάθλιψη, η αναιμία, η τριχόπτωση, η παχυσαρκία, η ενδομητρίωση, ο καρκίνος του μαστού, ο καρκίνος της μήτρας και ο καρκίνος των ωοθηκών· δ) θεραπεία ή/και πρόληψη των ασθενειών της οξείας ή/και χρόνιας μυϊκής εξασθένησης· ε) πρόληψη ή/και θεραπεία των ασθενειών ξηροφθαλμίας· ζ) στοματική θεραπεία αναπλήρωσης ανδρογόνου- η) μείωση της επιπτώσεως της αναστολής ή της πρόκλησης μίας παλινδρόμησης του καρκίνου του προστάτη· ή/και θ) πρόκληση
CY20091100794T 2002-10-16 2009-07-23 Αλογονομενοι επιλεκτικοι ρυθμιστες υποδοχεα ανδρογονων & μεθοδοι χρησης τους CY1109858T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/270,732 US6998500B2 (en) 2000-08-24 2002-10-16 Selective androgen receptor modulators and methods of use thereof
US10/371,213 US7026500B2 (en) 2000-08-24 2003-02-24 Halogenated selective androgen receptor modulators and methods of use thereof
EP03777595A EP1558565B1 (en) 2002-10-16 2003-10-14 Halogenated selective androgen receptor modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1109858T1 true CY1109858T1 (el) 2014-09-10

Family

ID=32109809

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100794T CY1109858T1 (el) 2002-10-16 2009-07-23 Αλογονομενοι επιλεκτικοι ρυθμιστες υποδοχεα ανδρογονων & μεθοδοι χρησης τους

Country Status (23)

Country Link
US (1) US7026500B2 (el)
EP (3) EP1764357A1 (el)
JP (4) JP4764719B2 (el)
KR (3) KR101069612B1 (el)
CN (3) CN100999481A (el)
AT (1) ATE430125T1 (el)
AU (1) AU2003287074B2 (el)
BR (1) BR0314891A (el)
CA (3) CA2588083A1 (el)
CY (1) CY1109858T1 (el)
DE (1) DE60327456D1 (el)
DK (1) DK1558565T3 (el)
EA (2) EA014932B1 (el)
ES (1) ES2324606T3 (el)
GE (2) GEP20084434B (el)
HK (1) HK1080070A1 (el)
HR (2) HRP20050334A2 (el)
IL (2) IL182880A0 (el)
MX (1) MXPA05004076A (el)
PT (1) PT1558565E (el)
SI (1) SI1558565T1 (el)
TW (1) TWI332955B (el)
WO (1) WO2004035736A2 (el)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) * 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20030232792A1 (en) * 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US7253210B2 (en) * 2002-10-15 2007-08-07 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
AU2002364949C1 (en) * 2001-12-06 2008-05-29 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
EP1592658B1 (en) * 2003-01-13 2013-04-24 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
AU2004206909A1 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (ADIF)-associated conditions with sarms
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
CN101721402B (zh) * 2003-10-14 2013-03-13 田纳西大学研究基金会 用选择性雄激素受体调节剂治疗骨相关病症
TW200533636A (en) * 2003-12-16 2005-10-16 Gtx Inc Prodrugs of selective androgen receptor modulators and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
GEP20094851B (en) * 2004-06-07 2009-12-10 The Univ Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EA200800710A1 (ru) * 2005-08-31 2008-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора
WO2007070682A2 (en) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
PL2038252T3 (pl) * 2006-07-12 2017-03-31 University Of Tennessee Research Foundation Podstawione acyloanilidy i sposoby ich zastosowania
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US9217129B2 (en) * 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
KR20100049644A (ko) 2007-08-07 2010-05-12 다케다 야쿠힌 고교 가부시키가이샤 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체
MX2010002784A (es) * 2007-09-11 2011-06-01 Univ Tennessee Res Foundation Formas solidas de moduladores selectivos del receptor de androgenos.
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
PL2644594T3 (pl) 2007-09-28 2018-01-31 Pfizer Ukierunkowanie na komórki nowotworowe za pomocą nanocząstek
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
WO2009082437A2 (en) 2007-12-21 2009-07-02 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (sarms) and uses thereof
ES2633792T3 (es) * 2008-05-07 2017-09-25 The Regents Of The University Of California Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
CN102686244A (zh) * 2009-04-21 2012-09-19 西莱克塔生物科技公司 提供一种Th1-偏向性应答的免疫纳米疗法
MX2012008110A (es) * 2010-01-11 2012-10-03 Gtx Inc Metodos para tratar una disfuncion de glandula de meibomio.
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
RU2483742C1 (ru) * 2012-07-18 2013-06-10 Татьяна Владимировна Буткова Способ лечения расстройств эрекции и расстройств полового влечения
PL3086784T3 (pl) * 2013-12-23 2019-09-30 Bcn Peptides, S.A. Analogi bikalutamidu lub (S)-bikalutamidu jako związki aktywujące egzocytozę do stosowania w leczeniu lizosomalnych chorób spichrzeniowych lub glikogenozy
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
RU2577225C1 (ru) * 2015-03-27 2016-03-10 Общество С Ограниченной Ответственностью "Парафарм" Препарат и способ для лечения дефицита андрогенов у женщин, содержащий энтомологические протеины
RU2620020C2 (ru) * 2015-10-06 2017-05-22 Рустем Фрунзевич Байкеев Способ идентификации сексуального статуса женщины с сексуальным либидо
EP3814272A4 (en) 2018-05-11 2022-03-02 Phosphorex, Inc. MICROPARTICLES AND NANOPARTICLES WITH NEGATIVE SURFACE CHARGES
JP2022532342A (ja) * 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022074152A1 (en) 2020-10-08 2022-04-14 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
JP2024510792A (ja) 2021-03-23 2024-03-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100046A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100044A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol
WO2024100040A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DE9217131U1 (de) * 1992-12-08 1993-03-11 Chr. Berghöfer GmbH & Co. KG, 3500 Kassel Armatur für einen Schlauch oder ein flexibles Rohr mit einer profilierten Außenfläche
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
WO1998053826A1 (en) 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP1222459A4 (en) 1999-10-14 2003-01-22 Bristol Myers Squibb Co CRYSTALLOGRAPHIC STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN
CZ20021340A3 (cs) 1999-10-19 2002-08-14 Nobex Corporation Způsoby asymetrické přípravy enantiomerů acylanilidů, jejich derivátů a meziproduktů pro uvedené přípravy
MXPA02004225A (es) 1999-10-27 2002-10-17 Nobex Corp Resolucion de intermediarios en la sintesis de bicalutamida sustancialmente pura.
EP1118811A3 (de) * 2000-01-19 2003-05-21 Witzenmann GmbH Flexibles Leitungselement mit einer an mindestens einem Ende angebrachten Anschlussvorrichtung
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
EA014224B1 (ru) 2000-08-24 2010-10-29 Юниверсити Оф Теннесси Рисерч Фаундейшн Селективные модуляторы андрогенового рецептора и способы их применения
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
AU2002364949C1 (en) * 2001-12-06 2008-05-29 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
BRPI0307699A2 (pt) * 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos

Also Published As

Publication number Publication date
CA2502355A1 (en) 2004-04-29
ATE430125T1 (de) 2009-05-15
JP2006514098A (ja) 2006-04-27
IL182880A0 (en) 2007-08-19
CN1726185B (zh) 2012-05-23
EP1558565A4 (en) 2006-04-19
WO2004035736A2 (en) 2004-04-29
CN100999481A (zh) 2007-07-18
PT1558565E (pt) 2009-07-09
GEP20084434B (en) 2008-07-25
BR0314891A (pt) 2005-08-02
EA200700854A1 (ru) 2007-12-28
JP4694529B2 (ja) 2011-06-08
AU2003287074B2 (en) 2009-12-10
TW200420571A (en) 2004-10-16
EP1558565A2 (en) 2005-08-03
EA200500648A1 (ru) 2006-06-30
JP4764719B2 (ja) 2011-09-07
CN101062023A (zh) 2007-10-31
CA2538095C (en) 2009-12-22
TWI332955B (en) 2010-11-11
JP2006199704A (ja) 2006-08-03
DE60327456D1 (de) 2009-06-10
EP1764357A1 (en) 2007-03-21
WO2004035736A3 (en) 2004-07-15
JP2007211024A (ja) 2007-08-23
CA2538095A1 (en) 2004-04-29
KR101069612B1 (ko) 2011-10-05
HK1080070A1 (en) 2006-04-21
CN1726185A (zh) 2006-01-25
KR20110004489A (ko) 2011-01-13
HRP20070457A2 (en) 2008-05-31
EP1558565B1 (en) 2009-04-29
GEP20094820B (en) 2009-11-10
EA011744B1 (ru) 2009-06-30
JP2011052027A (ja) 2011-03-17
US20040029913A1 (en) 2004-02-12
AU2003287074A2 (en) 2004-05-04
SI1558565T1 (sl) 2009-10-31
HRP20050334A2 (en) 2005-12-31
CA2588083A1 (en) 2004-04-29
AU2003287074A1 (en) 2004-05-04
EA014932B1 (ru) 2011-04-29
KR20070064441A (ko) 2007-06-20
MXPA05004076A (es) 2005-12-05
IL190931A0 (en) 2008-11-03
US7026500B2 (en) 2006-04-11
KR101068779B1 (ko) 2011-09-30
DK1558565T3 (da) 2009-08-24
ES2324606T3 (es) 2009-08-11
KR101107031B1 (ko) 2012-01-25
KR20050083771A (ko) 2005-08-26
EP2305636A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
CY1109858T1 (el) Αλογονομενοι επιλεκτικοι ρυθμιστες υποδοχεα ανδρογονων & μεθοδοι χρησης τους
CY1106486T1 (el) Μεθοδος παρασκευης 2-(κινοξαλιν-5-υλσουλφονυλαμινο) βενζαμιδικων ενωσεων
DE60229224D1 (de) Nociceptin-analoga
ES556289A0 (es) Procedimiento para la obtencion de derivados del acido (met)-acrilico de triciclodecanos.
AR019486A1 (es) Compuesto derivado de benzoxazol, benzotiazol y bencimidazol; procesos para prepararlo; composiciones que lo comprenden, metodos para combatir y controlar hongos e insectos, acaros, nematodos y moluscos.
ES556288A0 (es) Procedimiento para la obtencion de derivados del acido (met)-acrilo de triciclodecanos.
DE69616593D1 (de) Phenylimidazolidine und deren verwendung als anti-androgene mittel
DK1024137T3 (da) Opspaltning af aminer
ATE68472T1 (de) Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide.
ATE158919T1 (de) Verfahren und herbizide zusammensetzungen, die substituierte cyclohexandione und stickstoffdünger enthalten
DE50309260D1 (de) Verfahren zur herstellung von bicalutamid
CO5540311A2 (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos
HUP0001009A2 (hu) Herbicid hatású 3-karbamoil/3-tiokarbamoil-szubsztituált 2-benzoil-ciklohexán-1,3-dionok, intermedierjeik, előállításuk és alkalmazásuk
EA199800242A1 (ru) Амиды карбамоилкарбоновой кислоты
NO892189L (no) Trijodbenzenforbindelser og kontrastmidler for radiografiinneholdende disse.
NO995289L (no) Benzimidazol-derivater
DK0945430T3 (da) N-phenylacetoacetamider og fremgangsmåde til fremstilling deraf
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
SE8304315D0 (sv) Mutteralkaloide, ihre herstellung und verwendung
ATE84031T1 (de) Substituierte furazane.
PT96805A (pt) Processo para a preparacao de 2,4,8-tri-substituido-3h,6h-1,4,5a,8a-tetra-aza-acenaftileno-3,5-(4h)-dionas
DK508385A (da) Aminosyreestere
ES8606245A1 (es) Procedimiento para preparar fenoxianilinas y piridiloxianilinas sustituidas
RU93054538A (ru) N-алкоксамиды коричной кислоты, способ их получения, средства на их основе и применение
PT1414812E (pt) Derivados do acido hidroxamico